A Phase 1/2 interventional study of Aripiprazole and Aripiprazole in Schizophrenia and Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 39th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2019, is one of 2 in phase 1/2, and was the 118th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 266 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 41st largest by enrollment of the 111 interventional ones that give a count, is one of 13 that started in 2019, is the only one in phase 1/2, and was the 94th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following the final administration of aripiprazole into the gluteal muscle site, and to establish the similarity of aripiprazole exposure over the dosing interval following the administration of aripiprazole into the gluteal muscle site in adult participants with schizophrenia or bipolar I disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with schizophrenia or bipolar I disorder received aripiprazole 2 month (2M) long-acting injection (LAI) 960 milligrams (mg) for a total of 4 injections administered every 56 days (± 2 days) over the course of 32 weeks.
Drug: Aripiprazole
Participants with schizophrenia or bipolar I disorder received aripiprazole IM 400 mg, for a total of 8 injections administered every 28 days (± 2 days) over the course of 32 weeks.
Drug: Aripiprazole
Administered as an intramuscular (IM) depot injection.
Also known as: OPC-14597, Lu AF41155
Administered as an IM depot injection.
Also known as: OPC-14597, Lu AF41155
Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A TEAE is defined as an AE that started after investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption, or reduction of the IMP.
Time frame: From first dose of study drug up to 56 days (2M LAI 960 mg) or 28 days (IM depot 400 mg) post last dose of study drug (up to approximately 11 months)
Number of Participants With Potentially Clinically Relevant Vital Signs Abnormalities
Potentially clinically significant vital sign abnormalities included: heart rate supine (high: \>120 beats per minute \[BPM\] and increase \>=15 BPM; low: \<50 BPM and decrease \>=15 BPM), systolic blood pressure supine (high \>180 (millimetres of mercury \[mmHg\] and increase \>=20 mmHg); low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure supine (high: \>105 mmHg and increase \>=15 mmHg; low: \<50 mmHg and decrease \>=15 mmHg), heart rate standing (high: \>120 BPM and increase \>=15 BPM), systolic blood pressure standing (high: \>180 mmHg and increase \>= 20 mmHg; low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure standing (high: \>105 mmHg and increase \>=15 mmHg), weight in kilograms (kg) (high: increase \>=7%; low: decrease \>=7%), temperature (high: \>=37.8 degree celsius \[°C\] and increase \>=1.1°C), orthostatic hypotension (low: \>=20 mmHg decrease in systolic blood pressure and \>=25 BPM increase in heart rate from supine to standing.
Time frame: From first dose of study drug up to Day 225
Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
Potentially clinically significant ECG abnormalities included rate: bradycardia (vent \<=50 BPM\] and decrease \>=15 BPM); rhythm: sinus bradycardia (\<= 50 BPM and decrease \>= 15 BPM and no current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality); supraventricular premature beat (not present at baseline and present post baseline); ventricular premature beat (not present at baseline and present post baseline); conduction: right bundle branch block (not present at baseline and present post baseline); ST/T morphology: myocardial ischemia and symmetrical T-wave inversion (not present at baseline and present post baseline), QTcB, QTcF, and QTcN (\>=450 milliseconds \[msec\] and \>= 10% increase).
Time frame: From first dose of study drug up to Day 225
Number of Participants With Potentially Clinically Relevant Clinical Laboratory Abnormalities
Potentially clinically relevant laboratory abnormalities included: In units per liter \[U/L\] (alanine aminotransferase: male\[M\]/female\[F\] \>=3 x upper limit of normal (ULN); aspartate aminotransferase: M/F \>= 3 x ULN; creatine kinase: M/F \>= 3 x ULN); in milligrams per deciliter (mg/dL) (creatinine: M/F \>= 2.0; glucose: M/F \>= 200; urate: M \>=10.5, F \>=8.5); potassium \[milliequivalents per liter (mEq/L)\]: M/F \>=5.5, in percentage (%) (eosinophils/leukocytes: M/F\>=10%, hematocrit: M\<=37%/F\<=32% and 3 point decrease from baseline); hemoglobin (grams per deciliter \[g/dL\]): M\<=11.5/F\<=9.5; leukocytes \[10\^9 per liter (/L)\]: M/F\<=2.8 x 10\^3 per microliters (/uL); platelets (10\^9/L): M/F\>=700 x 10\^3/uL; glucose, urine and protein, urine: increase of \>=2 units; and prolactin (nanograms per milliliter \[ng/mL\]: M/F \> 1 x ULN.
Time frame: From first dose of study drug up to Day 225
Mean Change From Baseline in Simpson-Angus Neurologic Rating Scale (SAS) Total Score
The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.
Time frame: Baseline, Week 32
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Score
The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, aware/severe distress). AIMS movement score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.
Time frame: Baseline, Week 32
Mean Change From Baseline in Barnes Akathisia Rating Score (BARS) Global Score
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. Total BARS score ranges from 0 to 14 where lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
Time frame: Baseline, Week 32
Visual Analog Scale (VAS) Scores for Pain Perception of Aripiprazole 2M LAI 960 mg
Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).
Time frame: Day 1 (First injection) to Day 169 (Last injection)
VAS Scores for Pain Perception of Aripiprazole IM Depot 400 mg
Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).
Time frame: Day 1 (First injection) to Day 197 (Last injection)
Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole 2M LAI 960 mg Injection
Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.
Time frame: Day 1 (First injection) to Day 169 (Last injection)
Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole IM Depot 400 mg Injection
Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.
Time frame: Day 1 (First injection) to Day 197 (Last injection)
Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Suicidality was defined as reporting any suicidal ideation or behavior.
Time frame: Baseline to Day 225
Plasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose
Time frame: Day 225
Plasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose
Time frame: Day 225
Area Under the Plasma Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of Aripiprazole After the Seventh and Eighth Doses of Aripiprazole IM Depot 400 mg
Time frame: Days 169 (predose and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197 (predose and 4, 8, 12 hours post dose), 198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Area Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg
Time frame: Days 169 (predose and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197, 204, 211, 218, and 225
Maximum Observed Plasma Concentration (Cmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
Time frame: Days 1(predose [within 2 hours(h) prior to dosing]&4,8,12 h postdose),2,3,5,8,10,13,15,18,22,29,36,43,50,57(predose),85,113(predose),141,169(predose [within 2 h prior to dosing]& 4,8,12 h postdose),170,171,173,176,178,181,183,186,190,197,204,211,218 & 225
Time to Reach the Maximum Plasma Concentration (Tmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
Time frame: Days 1(predose [within 2 hours(h) prior to dosing]&4,8,12 h postdose),2,3,5,8,10,13,15,18,22,29,36,43,50,57(predose),85,113(predose),141,169(predose [within 2 h prior to dosing]& 4,8,12 h postdose),170,171,173,176,178,181,183,186,190,197,204,211,218 & 225
AUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg
Time frame: Days 1 (predose and 4, 8, 12 hours post-dose), 2, 3, 5, 8, 10, 13, 15, 18, 22, 29, 36, 43, 50 and 57 (pre-dose)
Plasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg
Time frame: Predose on Day 57
AUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg
Time frame: Days 169 (predose and 4, 8, 12 hours postdose), 170, 171, 173, 176, 178, 181, 183, 186, 190, and 197
Area Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
Time frame: Days 204, 211, 218, and 225
Peak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following fourth dose.
Time frame: Days 169 (Predose [within 2 hours prior to dosing] and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197, 204, 211, 218, and 225
Cmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
Time frame: Predose [within 2 hours prior to dosing; 4,8,12h postdose] on Days 1,169,197; Predose on Days 29,57,85,113,141; and on Days 2, 3, 5, 8, 10, 13, 15, 18, 22, 170, 171, 173, 176, 178, 181, 183, 186, 190,198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Tmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
Time frame: Predose [within 2 hours prior to dosing; 4,8,12h postdose] on Days 1,169,197; Predose on Days 29,57,85,113,141; and on Days 2, 3, 5, 8, 10, 13, 15, 18, 22, 170, 171, 173, 176, 178, 181, 183, 186, 190,198, 199, 201, 204, 206, 209, 211, 214, 218, 225
AUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg
Time frame: Days 1 (predose and 4, 8, and 12 hours postdose), 2, 3, 5, 8, 10, 13, 15, 18, 22 and 29 (predose)
Plasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg
Time frame: Predose on Day 29
PTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg
PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following eighth dose.
Time frame: Days 197 (Predose [within 2 hours prior to dosing] and 4, 8, 12 hours post dose),198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Plasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg
Time frame: Day 8
Plasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg
Time frame: Day 15
Mean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worse condition. The PANSS was assessed for schizophrenia participants only.
Time frame: Baseline, Week 32
Mean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The cumulative score range is 0-7. A higher score on the CGI-S represents a higher severity of disease. The CGI-S scale was assessed for schizophrenia participants only.
Time frame: Baseline, Week 32
Mean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score
The CGI-I scale is a clinician rated scale which assesses the improvement of illness for each participant. To assess CGI-I, the rater or investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared with the participant's condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Scores range from 0 to 7. Higher scores indicate worse condition.
Time frame: Baseline, Week 32
Mean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score
The participant's feeling of their own well-being was assessed using the 20-question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of well-being while receiving antipsychotic medication. The questionnaire consisted of 20 items (10 positive and 10 negative statements) and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', the response choices and scoring is not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, and very much = 6. For items marked with a '- ', the scoring is reversed; response choices and scoring are as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 1 (none) to 6 (severe), and total score ranged from 20 to 120, with higher scores indicating stronger subjective feeling
Time frame: Baseline, Week 32
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. This scale consists of 10 items each with 7 defined grades of severity on 0 to 6 scale (reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). MADRS total score is sum of 10 individual item scores ranging from 0-60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher score indicates more depressive symptoms. The MADRS was assessed for bipolar I disorder participants only.
Time frame: Baseline, Week 32
Mean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
The YMRS is an 11-item, multiple-choice diagnostic questionnaire which psychiatrists use to assess the core symptoms of mania and is based on the participants subjective report of their condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score is summed of 11 items. Total score range is from 0 to 60 and the higher score represent a worse outcome. The YMRS was assessed for bipolar I disorder participants only.
Time frame: Baseline, Week 32
Mean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score
The CGI-BP scale refers to the global impression of the participants with respect to bipolar disorder. The scale rates the participant's severity of illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and change from preceding phase (CGI-BP change from preceding phase: mania, depression, and overall bipolar illness) based on a 7-point scale ranging from 1 (normal, not ill) to 7 (very severely ill). A negative change score signifies improvement. The CGI-BP was assessed for bipolar I disorder participants only.
Time frame: Baseline, Week 32
Participants were enrolled in the study at 16 investigational sites in the United States from 01 August 2019 to 08 July 2020.
| Milestone | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Started | 132 | 134 |
| Safety sample | 132 | 134 |
| Efficacy sample | 132 | 134 |
| Completed | 102 | 92 |
| Not completed | 30 | 42 |
| Withdrew: Adverse event | 5 | 10 |
| Withdrew: Lost to follow-up | 3 | 7 |
| Withdrew: Protocol deviation | 2 | 2 |
| Withdrew: Withdrawal by subject | 16 | 18 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Due to covid-19 | 2 | 3 |
| Withdrew: Not due to covid-19 | 1 | 1 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A TEAE is defined as an AE that started after investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption, or reduction of the IMP.
| Participants | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs) | 94 | 95 |
Potentially clinically significant vital sign abnormalities included: heart rate supine (high: \>120 beats per minute \[BPM\] and increase \>=15 BPM; low: \<50 BPM and decrease \>=15 BPM), systolic blood pressure supine (high \>180 (millimetres of mercury \[mmHg\] and increase \>=20 mmHg); low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure supine (high: \>105 mmHg and increase \>=15 mmHg; low: \<50 mmHg and decrease \>=15 mmHg), heart rate standing (high: \>120 BPM and increase \>=15 BPM), systolic blood pressure standing (high: \>180 mmHg and increase \>= 20 mmHg; low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure standing (high: \>105 mmHg and increase \>=15 mmHg), weight in kilograms (kg) (high: increase \>=7%; low: decrease \>=7%), temperature (high: \>=37.8 degree celsius \[°C\] and increase \>=1.1°C), orthostatic hypotension (low: \>=20 mmHg decrease in systolic blood pressure and \>=25 BPM increase in heart rate from supine to standing.
| Participants | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Heart Rate Supine: Low | 0 | 1 |
| Heart Rate Supine: High | 2 | 1 |
| Systolic Blood Pressure Supine: Low | 1 | 2 |
| Systolic Blood Pressure Supine: High | 0 | 1 |
| Diastolic Blood Pressure Supine: Low | 1 | 1 |
| Diastolic Blood Pressure Supine: High | 1 | 1 |
| Heart Rate Standing: High | 4 | 6 |
| Systolic Blood Pressure Standing: Low | 1 | 4 |
| Systolic Blood Pressure Standing: High | 0 | 2 |
| Diastolic Blood Pressure Standing: High | 2 | 3 |
| Weight: Low | 12 | 11 |
| Weight: High | 52 | 54 |
| Temperature: High | 4 | 4 |
| Orthostatic Hypotension: Low | 2 | 2 |
Potentially clinically significant ECG abnormalities included rate: bradycardia (vent \<=50 BPM\] and decrease \>=15 BPM); rhythm: sinus bradycardia (\<= 50 BPM and decrease \>= 15 BPM and no current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality); supraventricular premature beat (not present at baseline and present post baseline); ventricular premature beat (not present at baseline and present post baseline); conduction: right bundle branch block (not present at baseline and present post baseline); ST/T morphology: myocardial ischemia and symmetrical T-wave inversion (not present at baseline and present post baseline), QTcB, QTcF, and QTcN (\>=450 milliseconds \[msec\] and \>= 10% increase).
| Participants | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Bradycardia | 0 | 2 |
| Sinus Bradycardia | 0 | 2 |
| Supraventricular Premature Beat | 13 | 10 |
| Ventricular Premature Beat | 17 | 12 |
| Right Bundle Branch Block | 1 | 0 |
| Myocardial Ischemia | 3 | 7 |
| Symmetrical T-Wave Inversion | 12 | 12 |
| QTcB | 1 | 1 |
| QTcF | 0 | 1 |
| QTcN | 0 | 1 |
Potentially clinically relevant laboratory abnormalities included: In units per liter \[U/L\] (alanine aminotransferase: male\[M\]/female\[F\] \>=3 x upper limit of normal (ULN); aspartate aminotransferase: M/F \>= 3 x ULN; creatine kinase: M/F \>= 3 x ULN); in milligrams per deciliter (mg/dL) (creatinine: M/F \>= 2.0; glucose: M/F \>= 200; urate: M \>=10.5, F \>=8.5); potassium \[milliequivalents per liter (mEq/L)\]: M/F \>=5.5, in percentage (%) (eosinophils/leukocytes: M/F\>=10%, hematocrit: M\<=37%/F\<=32% and 3 point decrease from baseline); hemoglobin (grams per deciliter \[g/dL\]): M\<=11.5/F\<=9.5; leukocytes \[10\^9 per liter (/L)\]: M/F\<=2.8 x 10\^3 per microliters (/uL); platelets (10\^9/L): M/F\>=700 x 10\^3/uL; glucose, urine and protein, urine: increase of \>=2 units; and prolactin (nanograms per milliliter \[ng/mL\]: M/F \> 1 x ULN.
| Participants | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| High Alanine Aminotransferase (U/L) | 1 | 2 |
| High Aspartate Aminotransferase (U/L) | 0 | 2 |
| High Creatine Kinase (U/L) | 12 | 1 |
| High Creatinine (mg/dL) | 2 | 1 |
| High Glucose (mg/dL) | 7 | 3 |
| High Potassium (mEq/L) | 5 | 4 |
| High Urate (mg/dL) | 2 | 0 |
| High Eosinophils/Leukocytes (%) | 2 | 0 |
| Low Hematocrit (%) | 7 | 8 |
| Low Hemoglobin (g/dL) | 4 | 9 |
| Low Leukocytes (10^9/L) | 0 | 3 |
| High Platelets (10^9/L) | 0 | 1 |
| High Glucose, Urine | 5 | 6 |
| High Protein, Urine | 1 | 2 |
| High Prolactin (ng/mL) | 2 | 4 |
The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Baseline | 0.2 ± 0.6 | 0.2 ± 0.4 |
| Change From Baseline at Week 32 | -0.0 ± 0.7 | 0.1 ± 0.6 |
The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, aware/severe distress). AIMS movement score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Baseline | 0.1 ± 1.0 | 0.1 ± 0.7 |
| Change from Baseline at Week 32 | 0.0 ± 0.5 | -0.1 ± 0.6 |
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. Total BARS score ranges from 0 to 14 where lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Baseline | 0.1 ± 0.3 | 0.1 ± 0.3 |
| Change from Baseline at Week 32 | 0.1 ± 0.6 | 0.1 ± 0.4 |
Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| First Injection: Predose | 1.0 ± 1.29 |
| First Injection: Post dose | 3.7 ± 9.09 |
| Second Injection: Predose | 1.0 ± 2.32 |
| Second Injection: Post dose | 1.4 ± 2.78 |
| Third Injection: Predose | 1.0 ± 2.58 |
| Third Injection: Post dose | 2.0 ± 6.01 |
| Fourth Injection: Predose | 0.8 ± 1.02 |
| Fourth Injection: Post dose | 1.4 ± 4.38 |
| Last Injection: Predose | 0.8 ± 1.03 |
| Last Injection: Post dose | 1.4 ± 3.98 |
Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).
| score on a scale | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| First Injection: Predose | 1.6 ± 2.37 |
| First Injection: Post dose | 3.0 ± 5.28 |
| Second Injection: Predose | 1.5 ± 2.66 |
| Second Injection: Post dose | 1.6 ± 3.09 |
| Third Injection: Predose | 0.8 ± 1.10 |
| Third Injection: Post dose | 1.2 ± 2.09 |
| Fourth Injection: Predose | 0.7 ± 0.79 |
| Fourth Injection: Post dose | 1.1 ± 2.39 |
| Fifth Injection: Predose | 0.7 ± 0.82 |
| Fifth Injection: Post dose | 0.8 ± 1.12 |
| Sixth Injection: Predose | 0.8 ± 1.11 |
| Sixth Injection: Post dose | 0.8 ± 1.20 |
| Seventh Injection: Predose | 0.6 ± 0.77 |
| Seventh Injection: Post dose | 1.0 ± 2.30 |
| Eighth Injection: Predose | 0.6 ± 0.69 |
| Eighth Injection: Post dose | 0.8 ± 0.85 |
| Last Injection: Predose | 0.9 ± 1.00 |
| Last Injection: Post dose | 1.3 ± 2.62 |
Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.
| Participants | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| First Injection: Mild Pain | 11 |
| Second Injection: Mild Pain | 2 |
| Third Injection: Mild Pain | 5 |
| Fourth Injection: Mild Pain | 5 |
| Last injection: Mild Pain | 5 |
| First injection: Mild Redness | 3 |
| Third injection: Mild Redness | 1 |
| Last injection: Mild Redness | 1 |
Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.
| Participants | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| First Injection: Mild Pain | 7 |
| Second Injection: Mild Pain | 3 |
| Third Injection: Mild Pain | 7 |
| Fourth Injection: Mild Pain | 1 |
| Fifth Injection: Mild Pain | 3 |
| Seventh Injection: Mild Pain | 1 |
| Eighth Injection: Mild Pain | 1 |
| Last injection: Mild Pain | 3 |
| First injection: Mild Redness | 1 |
| Second injection: Mild Redness | 3 |
C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Suicidality was defined as reporting any suicidal ideation or behavior.
| Participants | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | 4 | 4 |
| ng/mL (nanogram per milliliter) | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Plasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose | 250 ± 128 |
| ng/mL | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Plasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose | 257 ± 162 |
| day*ng/mL | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| AUC0-28 After Seventh Dose (Day 169) | 7760 ± 4300 |
| AUC0-28 After Eighth Dose (Day 197) | 7840 ± 5170 |
| day*ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg | 14700 ± 7460 |
| ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Cmax After First Dose (Day 1) | 286 ± 203 |
| Cmax After Fourth Dose (Day 169) | 342 ± 157 |
| days | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Tmax After First Dose (Day 1) | 8.58 (3.92 to 55.9) |
| Tmax After Fourth Dose (Day 169) | 28.0 (0.930 to 49.0) |
| day*ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| AUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg | 9180 ± 4940 |
| ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Plasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg | 165 ± 91.7 |
| day*ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| AUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg | 7190 ± 3470 |
| day*ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg | 7500 ± 4200 |
PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following fourth dose.
| percentage fluctuation | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Peak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg | 63.4 ± 25.1 |
| ng/mL | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Cmax After First Dose (Day 1) | 280 ± 123 |
| Cmax After Seventh Dose (Day 169) | 339 ± 168 |
| Cmax After Eighth Dose (Day 197) | 344 ± 212 |
| days | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Tmax After First Dose (Day 1) | 9.04 (3.83 to 27.9) |
| Tmax After Seventh Dose (Day 169) | 6.97 (1.05 to 28.0) |
| Tmax After Eighth Dose (Day 197) | 4.07 (0 to 28.0) |
| day*ng/mL | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| AUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg | 5030 ± 2580 |
| ng/mL | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Plasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg | 112 ± 82.9 |
PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following eighth dose.
| percentage fluctuation | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| PTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg | 48.3 ± 19.0 |
| ng/mL | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Plasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg | 221 ± 178 |
| ng/mL | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|
| Plasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg | 229 ± 121 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worse condition. The PANSS was assessed for schizophrenia participants only.
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia | Aripiprazole IM Depot 400 mg: Schizophrenia |
|---|---|---|
| Mean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score | -2.6 ± 11.7 | -1.7 ± 8.5 |
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The cumulative score range is 0-7. A higher score on the CGI-S represents a higher severity of disease. The CGI-S scale was assessed for schizophrenia participants only.
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia | Aripiprazole IM Depot 400 mg: Schizophrenia |
|---|---|---|
| Mean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score | -0.3 ± 0.6 | -0.1 ± 0.7 |
The CGI-I scale is a clinician rated scale which assesses the improvement of illness for each participant. To assess CGI-I, the rater or investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared with the participant's condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Scores range from 0 to 7. Higher scores indicate worse condition.
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Mean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score | 3.4 ± 1.1 | 3.5 ± 1.1 |
The participant's feeling of their own well-being was assessed using the 20-question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of well-being while receiving antipsychotic medication. The questionnaire consisted of 20 items (10 positive and 10 negative statements) and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', the response choices and scoring is not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, and very much = 6. For items marked with a '- ', the scoring is reversed; response choices and scoring are as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 1 (none) to 6 (severe), and total score ranged from 20 to 120, with higher scores indicating stronger subjective feeling
| score on a scale | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Mean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score | 3.2 ± 15.8 | 0.5 ± 18.2 |
The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. This scale consists of 10 items each with 7 defined grades of severity on 0 to 6 scale (reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). MADRS total score is sum of 10 individual item scores ranging from 0-60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher score indicates more depressive symptoms. The MADRS was assessed for bipolar I disorder participants only.
| score on a scale | Aripiprazole 2M LAI 960 mg: Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Bipolar I Disorder |
|---|---|---|
| Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -3.5 ± 9.1 | -3.3 ± 12.5 |
The YMRS is an 11-item, multiple-choice diagnostic questionnaire which psychiatrists use to assess the core symptoms of mania and is based on the participants subjective report of their condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score is summed of 11 items. Total score range is from 0 to 60 and the higher score represent a worse outcome. The YMRS was assessed for bipolar I disorder participants only.
| score on a scale | Aripiprazole 2M LAI 960 mg: Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Bipolar I Disorder |
|---|---|---|
| Mean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score | -1.9 ± 7.1 | -4.7 ± 7.7 |
The CGI-BP scale refers to the global impression of the participants with respect to bipolar disorder. The scale rates the participant's severity of illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and change from preceding phase (CGI-BP change from preceding phase: mania, depression, and overall bipolar illness) based on a 7-point scale ranging from 1 (normal, not ill) to 7 (very severely ill). A negative change score signifies improvement. The CGI-BP was assessed for bipolar I disorder participants only.
| score on a scale | Aripiprazole 2M LAI 960 mg: Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Bipolar I Disorder |
|---|---|---|
| Mean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score | -0.2 ± 1.0 | -0.6 ± 1.2 |
Collected over From first dose of study drug up to 56 days (2M LAI 960 mg) or 28 days (IM depot 400 mg) post last dose of study drug (up to approximately 11 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | 1/132 (0.8%) | 6/132 (4.5%) | 92/132 (69.7%) |
| Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder | 0/134 (0%) | 8/134 (6%) | 92/134 (68.7%) |
| Event | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Hallucination, auditoryPsychiatric disorders | 2/132 | 0/134 |
| Cardiac ArrestCardiac disorders | 1/132 | 0/134 |
| CellulitisInfections and infestations | 1/132 | 0/134 |
| AkathisiaNervous system disorders | 1/132 | 1/134 |
| Psychotic DisorderPsychiatric disorders | 1/132 | 1/134 |
| Cholecystitis AcuteHepatobiliary disorders | 0/132 | 1/134 |
| Septic ShockInfections and infestations | 0/132 | 1/134 |
| Adenocarcinoma of ColonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/132 | 1/134 |
| DepressionPsychiatric disorders | 0/132 | 1/134 |
| Depressive SymptomPsychiatric disorders | 0/132 | 1/134 |
| Event | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder |
|---|---|---|
| Weight IncreasedInvestigations | 30/132 | 28/134 |
| Injection Site PainGeneral disorders | 24/132 | 12/134 |
| AkathisiaNervous system disorders | 13/132 | 12/134 |
| AnxietyPsychiatric disorders | 11/132 | 10/134 |
| InsomniaPsychiatric disorders | 10/132 | 11/134 |
| HeadacheNervous system disorders | 10/132 | 5/134 |
| ToothacheGastrointestinal disorders | 2/132 | 10/134 |
| ConstipationGastrointestinal disorders | 8/132 | 8/134 |
| DiarrhoeaGastrointestinal disorders | 6/132 | 1/134 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/132 | 2/134 |
Randomized sample consisted of all participants who were randomized.
| Age, Continuous(years) | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder | Total |
|---|---|---|---|
| Mean | 47.8 ± 10.8 | 46.8 ± 11.7 | 47.3 ± 11.3 |
| Sex: Female, Male(Participants) | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder | Total |
|---|---|---|---|
| Female | 42 | 48 | 90 |
| Male | 90 | 86 | 176 |
| Ethnicity (NIH/OMB)(Participants) | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 11 | 23 |
| Not Hispanic or Latino | 119 | 122 | 241 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder | Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder | Total |
|---|---|---|---|
| Race — White | 29 | 33 | 62 |
| Race — Black or African American | 99 | 95 | 194 |
| Race — Asian | 3 | 4 | 7 |
| Race — Other | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Aug 2019 to primary completion in Jul 2020, 11 months.
Results were first posted in Nov 2023, 3 years 4 months after primary completion. A results delay was requested in Jun 2021.
Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →